-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on AbbVie, Maintains $298 Price Target

Benzinga·06/23/2026 16:19:45
Listen to the news
Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $298 price target.